Management of Castration-Resistant Prostate Cancer: Envisioning a Chronic Disease Paradigm

This is a very exciting era in the management of castration-resistant prostate cancer (CRPC). The approval of several novel agents has given prostate cancer patients and their treating physicians many new and effective therapeutic options. Newly approved agents and those in the pipeline present the real possibility of prolonging survival and the hope of turning the disease into a chronic condition. Moving forward, focus will continue to be on defining the optimal use and sequencing of these agents and supporting the clinical trials needed to accomplish this task. In order for health care providers to take full advantage of these new therapies they must feel competent in their utilization.

This activity will focus on current treatment options, challenges, and considerations in treating patients with castration-resistant prostate cancer as well as optimizing patient outcomes, clinical application of new agents, sequencing strategies and potential combinations of agents.

Target Audience

This educational activity is designed to meet the needs of physicians, nurses, pharmacists, and other clinical professionals who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

  • Discuss prostate cancer disease progression and clinical criteria for defining CRPC
  • Describe the mechanism of action of newly approved agents and those under investigation for the treatment of CRPC
  • Review the most recent NCCN Guidelines and assess strategies to integrate the new and emerging therapies into cancer clinical practice for the treatment of CRPC
  • Evaluate patient and disease characteristics that influence treatment choice and formulate a management plan to address specific considerations
Additional information
Supporters: 

Jointly sponsored by NCCN and PleXus Communications.

Supported by educational grants from Astellas Scientific and Medical Affairs, Inc. and Medivation, Inc.; Bayer HealthCare Pharmaceuticals and Algeta US; Dendreon Corporation; and Janssen Biotech, Inc., administered by Janssen Services, LLC.

Course summary
Available credit: 
  • 0.75 Participation
  • 0.78 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician
Course opens: 
05/29/2013
Course expires: 
04/30/2014
Cost:
$0.00

James Mohler, MD
Associate Director and Senior-Vice President for Translational Research
Chair, Department of Urology
Professor of Oncology
Roswell Park Cancer Institute
Buffalo, New York

Leonard G. Gomella, MD, FACS
Chairman, Department of Urology
Associate Director of Clinical Affairs
Jefferson Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, Pennsylvania

Available Credit

  • 0.75 Participation
  • 0.78 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video and audio playback
  • Adobe Reader for certificate viewing/printing